- Trials with a EudraCT protocol (13)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
13 result(s) found for: Thrombomodulin.
Displaying page 1 of 1.
| EudraCT Number: 2012-002251-42 | Sponsor Protocol Number: 3-001 | Start Date*: 2012-11-05 | |||||||||||
| Sponsor Name: Asahi Kasei Pharma America Corporation | |||||||||||||
| Full Title: A RANDOMIZED, DOUBLE BLIND, PLACEBO–CONTROLLED, PHASE 3 STUDY TO ASSESS THE SAFETY AND EFFICACY OF ART-123 IN SUBJECTS WITH SEVERE SEPSIS AND COAGULOPATHY | |||||||||||||
| Medical condition: severe sepsis and coagulopathy | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) NL (Completed) HU (Completed) FI (Completed) CZ (Completed) ES (Completed) BG (Prematurely Ended) GB (Completed) DE (Completed) GR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-002998-11 | Sponsor Protocol Number: ENDO-RCA | Start Date*: 2014-11-14 | |||||||||||
| Sponsor Name:Rigshospitalet, Capital Region Bloodbank 2034, Section for Transfusion Medicine | |||||||||||||
| Full Title: Safety and efficacy of low-dose Iloprost administration and blood pressure target in addition to standard therapy, as compared to standard therapy alone, in post-cardiac- arrest-syndrome patients... | |||||||||||||
| Medical condition: Cardiac Arrest | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-001958-36 | Sponsor Protocol Number: SDX_01 | Start Date*: 2022-08-29 |
| Sponsor Name:Corporativo de Servicios Médicos Especializados S.A de C.V V (Centro Médico del Noroeste) | ||
| Full Title: Endothelial protection in convalecent COVID-19 patients. The effect of Sulodexide on serum levels of biomarkers for endothelial dysfunction. A prospective, randomized, placebo-controlled, investiga... | ||
| Medical condition: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by coronavirus 2 (SARS-CoV-2) and, thus, being a novel cause of sepsis and the the poor outcome of patients with sepsis was relat... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: HU (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-002586-34 | Sponsor Protocol Number: STEROID_MC_1 | Start Date*: 2020-11-12 | |||||||||||||||||||||||||||||||
| Sponsor Name:Department of Anesthesiology, Copenhagen University Hospital Hvidovre, Capital Region of Denmark | |||||||||||||||||||||||||||||||||
| Full Title: The effects of preoperative high-dose Dexamethasone on inflammatory response and recovery after emergency laparotomy, a randomized, double-blind, placebo-controlled clinical trial - AHA STEROID ... | |||||||||||||||||||||||||||||||||
| Medical condition: Patients undergoing emergency laparotomy due to either Intestinal obstruction or perforated abdominal viscus. | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2007-002035-81 | Sponsor Protocol Number: 2-001 | Start Date*: 2007-10-22 | ||||||||||||||||
| Sponsor Name:Artisan Pharma, Inc. | ||||||||||||||||||
| Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy Effects of ART-123 on Subjects with Sepsis and Disseminated Intravascular Coagulation | ||||||||||||||||||
| Medical condition: Sepsis and disseminated intravascular coagulation. | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (Completed) ES (Completed) CZ (Completed) BE (Completed) NL (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2016-000707-81 | Sponsor Protocol Number: VIPER-SEPSIS | Start Date*: 2016-04-26 | |||||||||||
| Sponsor Name:Section for Transfusion Medicine, Capitol Region Blood Bank | |||||||||||||
| Full Title: Vasculopathic Injury and Plasma as Endothelial Rescue in septic shock (SEPSIS) trial | |||||||||||||
| Medical condition: Patients with septic shock admitted to the intensive care unit | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-002686-19 | Sponsor Protocol Number: 2018-HJEPharma-001 | Start Date*: 2018-11-07 | |||||||||||
| Sponsor Name:Department of Cardiology, Copenhagen University Hospital Rigshospitalet | |||||||||||||
| Full Title: Interleukin-6 Receptor Antibodies for Modulating the Systemic Inflammatory Response after Out-of-Hospital Cardiac Arrest | |||||||||||||
| Medical condition: We investigate the efficacy of commercially available interleukin-6 receptor antibody 'RoActemra' for reducing the systemic inflammatory response in patients having been resuscitated after out-of-h... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-004261-24 | Sponsor Protocol Number: CL006_168 | Start Date*: 2015-05-08 | |||||||||||
| Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI | |||||||||||||
| Full Title: AN OPEN-LABEL PHASE 2 STUDY TO ASSESS THE EFFECT OF C5AR ANTAGONIST THERAPY BY CCX168 ORAL ADMINISTRATION ON EX VIVO THROMBUS FORMATION AND DISEASE ACTIVITY IN ESRD PATIENTS WITH ATYPICAL HEMOLYTI... | |||||||||||||
| Medical condition: Atypical Hemolytic Uremic Syndrome | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-000427-27 | Sponsor Protocol Number: VIPER-SHOCK | Start Date*: 2017-03-30 | |||||||||||
| Sponsor Name:Section for Transfusion Medicine, Capitol Region Blood Bank | |||||||||||||
| Full Title: Vasculopathic Injury and Plasma as Endothelial Rescue in septic shock (SHOCK) trial | |||||||||||||
| Medical condition: Patients with septic shock admitted to the intensive care unit. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-001949-20 | Sponsor Protocol Number: 1.0 | Start Date*: 2023-01-09 | |||||||||||
| Sponsor Name:ALBIMMUNE S.L. | |||||||||||||
| Full Title: Human albumin treatment in adult septic shock. A phase 2, multicenter, randomized, controlled study evaluating the immune response and organ failure. | |||||||||||||
| Medical condition: Septic Shock | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2012-005682-12 | Sponsor Protocol Number: H-2-2012_089 | Start Date*: 2013-07-03 | ||||||||||||||||||||||||||
| Sponsor Name:Dept. of Clinical Immunology | ||||||||||||||||||||||||||||
| Full Title: THE EFFECT OF PLASMA ON THE ENDOTHELIUM IN CRITICAL ILLNESS | ||||||||||||||||||||||||||||
| Medical condition: Pilot study in healthy subjects with a perspective for treating of serious conditions such as sepsis, septic shock, trauma and severe haemorrhage | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults | Gender: Male | |||||||||||||||||||||||||||
| Trial protocol: DK (Completed) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2010-020763-20 | Sponsor Protocol Number: 10072DMcA-CS | Start Date*: 2010-10-04 |
| Sponsor Name:National University of Ireland, Galway | ||
| Full Title: Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP 2) | ||
| Medical condition: Acute lung injury | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: IE (Completed) GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2018-000246-19 | Sponsor Protocol Number: 3-3002 | Start Date*: 2018-09-24 | ||||||||||||||||
| Sponsor Name:Asahi Kasei Pharma America Corporation | ||||||||||||||||||
| Full Title: SCARLET-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects with Sepsis and Coagulopathy | ||||||||||||||||||
| Medical condition: Sepsis, defined by the presence of infection and host inflammation, is a lethal clinical syndrome. In severe disease, the coagulation system becomes diffusely activated, with consumption of multipl... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.